## Total Synthesis of $(\pm)$ -Otteliones A and B\*\*

Goverdhan Mehta\* and Kabirul Islam

The isolation of the two diastereomeric otteliones A and B from the widely occurring but little studied fresh water plant *Ottelia alismoides*, and the determination of their structures, which include a unique 4-methylenecyclohex-2-enone substructure, was reported in 1998.<sup>[1]</sup> Collaborative efforts between US and Egyptian scientists, who employed high-field NMR spectroscopy techniques and modeling studies, led to the stereostructure 1 for ottelione B. However, the

structure of ottelione A could not be assigned unambiguously, and both 2a and 2b were considered as likely formulations, the former being more likely.[1] In 2000, scientists at Rhône-Poulenc Rohrer reinterpreted<sup>[2]</sup> the NMR spectroscopic data and proposed an alternate stereostructure 2c for ottelione A (RPR 112378). Otteliones have attracted much attention as they exhibit remarkable, broad-ranging biological activity.[1-4] Chinese scientists have reported the antitubercular effect of extracts of Ottelia alismoides, which is rich in otteliones, and have shown in clinical trials that two cases of bilateral tuberculosis of the cervical lymph gland were cured in three months.[3] At the National Cancer Institute, in vitro screening against a panel of 60 human cancer cell lines showed that otteliones exhibited cytotoxicity at nm-pm levels.[1,4] More recent results have shown that ottelione A is an efficient inhibitor of tubulin polymerization (IC<sub>50</sub> = 1.2  $\mu$ M) and is able to disassemble preformed microtubules in a manner reminiscent of the colchicines, vinblastine, and vincristine.[2] The cytotoxicity of otteliones can be attributed to the presence of

<sup>[\*]</sup> Prof. G. Mehta, K. Islam Department of Organic Chemistry, Indian Institute of Science Bangalore-560012 (India) Fax: (+91) 80-360-0936 E-mail: gm@orgchem.iisc.ernet.in


<sup>[\*\*]</sup> We would like to thank Professor Thomas R. Hoye for the NMR spectroscopic data for the otteliones for comparison purposes. K.I. thanks the CSIR (India) for a research fellowship.

Supporting information for this article is available on the WWW under http://www.angewandte.org or from the author.

the unique electrophilic 4-methylenecyclohex-2-enone moiety that engages the sulfhydryl groups of the cysteine residues on the tubulin and disrupts the microtubule dynamics; this suggests a mechanism of action similar to that of T138067, a cytotoxic molecule with antitumor activity that reacts specifically with cysteine residue 239 in  $\beta$ -tubulin and is proposed to bind in the close vicinity of the colchicine-binding site [2, 5-7] In

suggests a mechanism of action similar to that of T138067, a cytotoxic molecule with antitumor activity that reacts specifically with cysteine residue 239 in  $\beta$ -tubulin and is proposed to bind in the close vicinity of the colchicine-binding site. [2, 5–7] In view of the structural ambiguity and complexity, exceptional therapeutic potential, and the desirability to access analogues, otteliones have aroused considerable synthetic interest. The presence of four contiguous stereogenic centers, the *cis*-hydrindane moiety with side chains at C6 and C8, and the rare and sensitive 4-methylenecyclohex-2-enone functionality make otteliones challenging synthetic targets. We report herein the first total synthesis of racemic otteliones A and B through a short and flexible strategy that fully secures their structure and has potential for accessing diverse analogues. [8, 9]

The key to our synthetic strategy towards otteliones **1** and **2** was the choice of the readily available Diels – Alder adduct **3** of cyclopentadiene and benzoquinone as the starting point (Scheme 1).<sup>[10]</sup> We recognized that **3** embodies a readily



TiCl<sub>4</sub> – CH<sub>2</sub>Br<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 0°C, 71%; c) 1) O<sub>3</sub>, MeOH, -78°C; 2) Me<sub>2</sub>S, room temperature, 70%; d) Ph<sub>3</sub>PCH<sub>3</sub>+I-, nBuLi, THF, 0°C, 89%; e) PCC, CH<sub>2</sub>Cl<sub>2</sub>, 0°C, 91%. PCC = pyridinium chlorochromate.

extractable *cis*-hydrindane framework (see bold lines in 3) whose functionalities can be differentiated and elaborated in a regio- and stereoselective manner to the substitution and functionalization pattern of the natural products. Lithium aluminum hydride reduction of 3 led to both 1,4- and 1,2-reduction to furnish the tricyclic hydroxy ketone 4.<sup>[11]</sup> Lombardo methylenation<sup>[12]</sup> of 4 smoothly delivered 5 and

set the stage for unraveling the hydrindane moiety. Controlled

ozonolysis of 5 delivered 6 and 7 (8:1).[11] The major product

of the reaction, the lactol aldehyde 6 originated through the


intramolecular capture of one of the aldehyde moieties of the

intermediate dialdehyde **8** by the appropriately positioned α-hydroxy group and concomitant epimerization of the second aldehyde group to the thermodynamically more stable *exo* orientation. The minor product of the ozonolysis reaction, the dome-shaped pentacyclic ether **7**, was derived through a cascade intramolecular acetalization process in the intermediate keto dialdehyde **9**, which is formed through the oxidative cleavage of both olefinic bonds of **5** (Scheme 1). Wittig olefination of **6** installed the vinyl side chain of **10** with the correct stereochemistry. PCC oxidation of lactol **10** delivered the crystalline lactone **11** whose stereostructure corresponded to the revised<sup>[2]</sup> formulation **2c** of ottelione **A** and was

We next focused on the introduction of the benzylic side chain at C8 by utilizing the lactone functionality of 11. The organolithium reagent derived from 12 readily added to 11 to furnish 13, which was further deoxygenated through lithium/ammonia reduction (Scheme 2). This protocol also released the hydroxy group at C1 to yield 14. PCC oxidation of 14 to the cyclohexanone 15 was straightforward and set the stage for the generation of the crucial 4-methylenecyclohex-2-

fully secured through single-crystal X-ray structure determi-

nation.



Scheme 2. Reagents and conditions: a) nBuLi, THF,  $-78^{\circ}C \rightarrow RT$ , 82%; b) Li, liquid NH<sub>3</sub>, THF,  $-33^{\circ}C$ , 63%; c) PCC, CH<sub>2</sub>Cl<sub>2</sub>, 0°C, 89%; d) 1) LHMDS, PhSeCl, THF,  $-78^{\circ}C$ ; 2) H<sub>2</sub>O<sub>2</sub> (30%), CH<sub>2</sub>Cl<sub>2</sub>, 0°C, 61% over two steps; e) TBAF, THF, 0°C, 68%; f) DBU, benzene, 65°C, 83%. DBU = 1,8-diazabicyclo[5.4.0]undec-7-ene, LHMDS = lithium 1,1,1,3,3,3-hexamethyldisilazane, TBAF = tetrabutylammonium fluoride.

enone moiety, which was produced through the phenylselenation–selenoxide elimination sequence to give 16 (Scheme 2). Finally, fluoride-mediated cleavage of the TBS protecting group in 16 furnished ottelione A  $(2\,c)$ , whose spectra are identical to those of the natural product. [1, 2] Synthetic  $2\,c$  smoothly underwent epimerization at C9 on exposure to base (DBU) to give ottelione B (1), whose spectra match those of the natural product (Scheme 2).

To summarize, we have delineated an 11-step, regio- and stereocontrolled synthesis of the biologically potent natural products otteliones A and B from commercially available starting materials in 5.4% overall yield, and have thus fully secured their structures. Our approach is concise and flexible,

amenable to scale-up, geared to provide access to analogues, and involves only one protecting-group manipulation. [13]

- [3] H. Li, H. Li, X. Qu, Y. Shi, L. Guo, Z. Yuan, Zhongguo Zhongyao Zazhi (Chin. J. Chin. Mater. Med.) 1995, 20, 115, 128.
- [4] J. Leboul, J. Prevost, French Patent WO96/00205, 1996 [Chem. Abstr. 1996, 124, 242296].
- [5] The 4-methylenecyclohex-2-enone moiety has been rarely reported,<sup>[6]</sup> and therefore the interaction of this electrophilic chromophore with biological systems has remained unexplored.
- [6] a) D. F. Murray, M. W. Baum, M. Jones, J. Org. Chem. 1986, 51, 1;
  b) M. E. Jung, H. L. Rayle, Synth. Commun. 1994, 24, 197; c) H. Wild, J. Org. Chem. 1994, 59, 2748.
- [7] For the details of the interaction of tubulin with drugs and alkylating agents, see: a) R. Kuriyama, H. Sakai, J. Biochem. (Tokyo) 1974, 76, 651; b) R. F. Luduena, M. C. Roach, Biochemistry 1981, 20, 4444; c) B. Shan, J. C. Medina, E. Shanta, W. P. Franckmoelle, T. C. Chau, R. M. Learned, M. R. Narbut, D. Stott, P. Wu, J. C. Jean, T. Rosen, P. B. Timmermans, H. Beckmann, Proc. Natl. Acad. Sci. USA 1999, 96, 5686.
- [8] Our synthetic efforts towards the otteliones began towards the end of 1998, and were initially targeted towards  $2\mathbf{a}_i^{[9a]}$  the then favored structure<sup>[1]</sup> of ottelione A, and subsequently towards the other possible formulation  $2\mathbf{b}_i^{[9b]}$  In January 2001, we became aware<sup>[2]</sup> of the alternate formulation  $2\mathbf{c}_i$ , and efforts were directed towards this target. We have completed the total synthesis of  $2\mathbf{a} \mathbf{c}_i$  and several other diastereomers of otteliones A and B. Spectral data of  $2\mathbf{a}_i$ , did not match those of the natural product ottelione A (K. Islam, unpublished results).
- [9] a) G. Mehta, D. S. Reddy, *Chem. Commun.* 1999, 2193; b) G. Mehta,
   K. Islam, *Synlett* 2000, 1473; for other approaches to the otteliones,
   see: L. Trembleau, L. Patiny, L. Ghosez, *Tetrahedron Lett.* 2000, 41,
   6377
- [10] a) O. Diels, J. M. Blom, W. Koll, Justus Liebigs Ann. Chem. 1925, 443, 247; b) R. C. Cookson, E. Crundwell, R. R. Hill, J. Hudec, J. Chem. Soc. 1964, 3062.
- [11] All new compounds reported herein are racemic and fully characterized on the basis of IR and <sup>1</sup>H and <sup>13</sup>C NMR spectroscopic data, mass spectrometry, and elemental analyses (see Supporting Information)
- [12] L. Lombardo, Tetrahedron Lett. 1982, 23, 4293.
- [13] Although the plant Ottelia alismoides is regarded as a weed and is widely distributed along irrigation canal linings and rice fields in the Afro-Asian region, otteliones A and B are present only at ppm levels; thus synthetic access through practical routes is necessary to evaluate their biological potential.

S. E. N. Ayyad, A. S. Judd, W. T. Shier, T. R. Hoye, J. Org. Chem. 1998, 63, 8102.

<sup>[2]</sup> C. Combeau, J. Provost, F. Lanceli, Y. Tournoux, F. Prod'homme, F. Herman, F. Lavelle, J. Leboul, M. Vuilhorgne, Mol. Pharm. 2000, 57, 553